Clinical Trial Update: A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SB11 (ranibizumab biosimilar) to Lucentis in neovascular age-related macular degeneration has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• SB11 (Proposed Ranibizumab biosimilar) (ranibizumab)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2021-05-21